Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of Ganfeborole and Oral Contraceptive
NCT06354257Phase 1Completed
- Sponsor
- GSK
- Start
- Apr 2024
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ganfeborole in Tuberculosis (TB), sponsored by GSK. Primary endpoints: Area Under the Plasma Drug Concentration From Time Zero Extrapolated to Infinity After a Single Dose of EE and LNG at Day 15 and Maximum Observed Plasma Concentration After a Single Dose of EE and LNG at Day 15. Started Apr 2024; status: completed.
02
Drugs
ganfeborole
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT06354257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06354257.